StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Equities researchers at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the stock.

EKSO has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a research note on Tuesday, January 14th. Lake Street Capital dropped their price objective on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th.

Ekso Bionics Trading Down 2.6 %

EKSO stock opened at $0.55 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The firm has a fifty day moving average price of $0.63 and a 200 day moving average price of $0.84. The firm has a market cap of $12.01 million, a PE ratio of -0.84 and a beta of 1.46. Ekso Bionics has a fifty-two week low of $0.47 and a fifty-two week high of $2.16.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.